The type of KRAS mutation drives PI3Kα/γ signalling dependency: Implication for the choice of targeted therapy in pancreatic adenocarcinoma patients

Canon, 2019, The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity, Nature, 575, 217, 10.1038/s41586-019-1694-1 Hallin, 2020, The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients, Cancer Discov, 10, 54, 10.1158/2159-8290.CD-19-1167 Waters, 2018, KRAS: the critical driver and therapeutic target for pancreatic cancer, Cold Spring Harb Perspect Med, 8 Zeitouni, 2016, KRAS mutant pancreatic cancer: No lone path to an effective treatment, Cancers (Basel), 8, 1, 10.3390/cancers8040045 Lawrence, 2014, Discovery and saturation analysis of cancer genes across 21 tumour types, Nature, 505, 495, 10.1038/nature12912 Buscail, 2020, Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer, Nat Rev Gastroenterol Hepatol, 17, 153, 10.1038/s41575-019-0245-4 Baer, 2014, Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α, Genes Dev, 28, 2621, 10.1101/gad.249409.114 Wu, 2014, PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice, Gastroenterology, 147, 1405, 10.1053/j.gastro.2014.08.032 Eser, 2013, Selective requirement of PI3K/PDK1 signaling for kras oncogene-driven pancreatic cell plasticity and cancer, Cancer Cell, 23, 406, 10.1016/j.ccr.2013.01.023 Commisso, 2013, Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells, Nature, 497, 633, 10.1038/nature12138 Bar-Sagi, 1986, Induction of membrane ruffling and fluid-phase pinocytosis in quiescent fibroblasts by ras proteins, Science (80-), 233, 1061, 10.1126/science.3090687 Biancur, 2018, The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance, Biochim Biophys Acta - Rev Cancer, 1870, 67, 10.1016/j.bbcan.2018.04.011 Milane, 2015, Exosome mediated communication within the tumor microenvironment, J Control Release, 219, 278, 10.1016/j.jconrel.2015.06.029 Yao, 2019, Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer, Nature, 568, 410, 10.1038/s41586-019-1062-1 Hobbs, 2019, Atypical KRASG12R mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer, Cancer Discov Baer, 2015, Implication of PI3K/Akt pathway in pancreatic cancer: when PI3K isoforms matter?, Adv Biol Regul, 1 Gupta, 2007, Binding of ras to phosphoinositide 3-Kinase p110α is required for ras- driven tumorigenesis in mice, Cell, 129, 957, 10.1016/j.cell.2007.03.051 Suire, 2006, Gβγs and the Ras binding domain of p110γ are both important regulators of PI3Kγ signalling in neutrophils, Nat Cell Biol, 8, 1303, 10.1038/ncb1494 Rodriguez-Viciana, 1997, Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras, Cell, 89, 457, 10.1016/S0092-8674(00)80226-3 Pons-Tostivint, 2017, Targeting PI3K signaling in combination cancer therapy, Trends in Cancer, 3, 454, 10.1016/j.trecan.2017.04.002 Bryant, 2019, Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer, Nat Med, 25, 628, 10.1038/s41591-019-0368-8 Kinsey, 2019, Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers, Nat Med, 25, 620, 10.1038/s41591-019-0367-9 Bryant, 2019, Blocking autophagy to starve pancreatic cancer, Nat Rev Mol Cell Biol, 20, 265, 10.1038/s41580-019-0120-8 Rodon, 2018, A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors, Oncotarget, 9, 31709, 10.18632/oncotarget.25854 André, 2019, Alpelisib for PIK3CA -mutated, hormone receptor–positive advanced breast cancer, N Engl J Med, 380, 1929, 10.1056/NEJMoa1813904 Cintas, 2018, Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?, Front Oncol, 7, 1, 10.3389/fonc.2017.00330 Dou, 2015, Autophagy mediates degradation of nuclear lamina, Nature, 527, 105, 10.1038/nature15548 Basset, 2017, Attenuating PI3K isoforms in pancreatic cancer: Focus on immune PI3Kγ, Clin Res Hepatol Gastroenterol, 41, 351, 10.1016/j.clinre.2017.04.013 Edling, 2010, Key role of phosphoinositide 3-kinase class IB in pancreatic cancer, Clin Cancer Res, 16, 4928, 10.1158/1078-0432.CCR-10-1210 Cintas C, Douche T, Dantes Z, et al. Phosphoproteomics identifies PI3Kγ isoform-selective adaptive response to class I PI3K inhibition in cancer cell therapy and resistance. Submitted. Cintas, 2018, Signal-targeted therapies and resistance mechanisms in pancreatic cancer: Future developments reside in proteomics, Cancers (Basel), 10 Turajlic, 2019, Resolving genetic heterogeneity in cancer, Nat Rev Genet, 20, 404, 10.1038/s41576-019-0114-6 Mueller, 2018, Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes, Nature, 554, 62, 10.1038/nature25459 Bery, 2019, KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe, Nat Commun, 10, 0, 10.1038/s41467-019-10419-2